My most notable academic contribution has been in research that sought to improve the care of children with Wilms tumor and in understanding some of the biologic aspects of this paediatric renal malignancy. With regard to the latter I worked in one of the laboratories that cloned WT1, the Wilms tumor gene on chromosome 11p13 (Science 1990). I subsequently set out to determine the role of this gene and other genetic loci in the development of Wilms tumor (reviewed in NEJM 1994 and Cancer Invest 1994). Following my relocation to Calgary, my laboratory research changed focus to characterize tumors of patients with so-called favourable histology Wilms tumor who subsequently relapsed and in doing so establish predictors of relapse in favourable histology Wilma tumor. With regard to the clinical aspects of Wilms tumor, I was an active contributor and participant of the Nephroblastoma committee of the International Society for Paediatric Oncology and later the National Wilms Tumor Study Group. The identification of specific factors that can guide clinicians in assessing the risk of contralateral tumor development (Cancer 1999) is often used today to determine whether additional therapy should be given to very young patients, in particular if they are female, with Wilms tumor and nephrogenic rests.
From 1993 to 2007, I have been actively involved in childhood cancer clinical trials. I have been an active member of several tumor group committees (renal tumors, rare tumors, lymphomas) in North American clinical trials organizations (Pediatric Oncology Group, Children’s Cancer Group, and National Wilms Tumor Study Group).
From 2004 to 2006 I served as the first Senior Medical Officer for Canadian Affairs of the Children’s Oncology Group (COG). COG is an international consortium of approximately 220 pediatric cancer centers organized for the purpose of conducting clinical trials and biologic research in the area of pediatric cancer.
More recently, I have been actively involved in patient safety research and health economics. With regard to health economics, I have a special interest in affordability of cancer care, in particular chemotherapy, in publicly funded jurisdictions.
- Selove R, Kroll T, Coppes MJ, Cheng Y: Psychosocial services in the first 30 days after diagnosis: Results of a web-based survey of Children’s Oncology Group (COG) member institutions. Pediatric Blood and Cancer. Pediatric Blood and Cancer 58 (3): 435–440, 2012.
- Segers H, van den Heuvel-Eibrink MM, Coppes MJ, Bergeron C, de Camargo B, Dome JS, Gatta G, Graf N, Grundy P, Kalapuraka JA, de Kraker J, Perlman EJ, Reinhard H, Spreafico F, Vujanic G, Warwick AB, Pritchard-Jones K, on behalf of the SIOP-RTSG and the COG-RTC. Management of adults with Wilms tumor: recommendations based on international consensus Position paper by the Nephroblastoma Committee of the International Society of Paediatric Oncology (SIOP) and the Renal Tumors Committee (RTC) of the Children’s Oncology Group (COG). Expert review of Anticancer Therapy 11:1107-1115, 2011.
- Voss CY, Fry TJ, Coppes MJ, Blajchman MA. Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis. Transfusion Medicine Reviews 24:22-32, 2010.
- Shamberger RC, Anderson JR, Breslow NE, Perlman EJ, Beckwith JB, Ritchey ML, Haase GM, Donaldson M, Grundy PE, Weetman R, Coppes MJ, Malogolowkin M, Shearer PD, Kletzel M, Thomas PR, Macklis R, Huff V, Weeks DA, Green DM. Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. Annals of Surgery 251:555-558, 2010.
- Blackmore C, Coppes MJ, Narendran A. Candidate genes and potential targets for therapeutics in Wilms tumor. Clinical and Translational Oncology 12:597-605, 2010.
- Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PR, Grundy PE, D’Angio GJ, Beckwith JB, Shamberger RC, Haase GM, Donaldson M, Weetman R, Coppes MJ, Shearer P, Coccia P, Kletzel M, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatric Blood Cancer 50:236-241, 2008.
- Green DM, Cotton, CA, Malogolowkin M, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D’Angio GJ, Beckwith JB, Shamberger RC, Haase GM, Donaldson M, Weetman R, Coppes MJ, Shearer P, Coccia P, Kletzel M, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D. A report from the National Wilms Tumor Study Group. Pediatric Blood & Cancer 48:493-499, 2007.
- Metzger ML, Stewart CF, Freeman B, Billups C, Hoffer FA, Wu J, Coppes MJ, Grant R, Chintagumpala M, Mullen M, Alvarado C, Daw NC, Dome JS. Topotecan is active against Wilms tumor: results of a multi-Institutional phase II study. Journal of Clinical Oncology 25:3130-6, 2007.
- Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, Grundy PE, Malogolowkin M, Beckwith JB, Shamberger RC, Haase GM, Coppes MJ, Coccia P, Kletzel M, Weetman RM, Donaldson M, Macklis R, Green DM. Treatment of Anaplastic Histology Wilms Tumor: Results from the Fifth National Wilms Tumor Study. Journal of Clinical Oncology: 24: 2352-2358, 2006.
- Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes MJ, Fernandez C, Bouffet E. Safety and Pharmacokinetic of Temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours, European Journal of Cancer, 42:2335-2342, 2006.
- Coppes MJ, Campbell C, Williams BRG. Wilms Tumor: Clinical and Molecular Characterization. R.G. Landes Company, 1995.
- Coppes MJ. Wilms Tumor. A compilation of Clinical and Molecular Charateristics (PhD defence). The Cleveland Clinic Foundation, 1992.
- Kids Cancer Care Foundation Chair in Paediatric Oncology ($6 million endowment), Faculty of Medicine, University of Calgary, (2003-2005)
- Distinguished Professional Award, Calgary Immigrant Aid Society, Calgary, Alberta, (2001)
- Royal College Visiting Professorship in Medical Research, St. John’s, Newfoundland, (1997)
- Alberta Heritage Foundation for Medical Research Clinical Investigator, (1996-1999)
- Lil Faider Lecturer, Canadian Cancer Society, Alberta/ NWT Division, (1994)
- Fellowship, Research Training Committee, Hospital for Sick Children, Toronto, Ontario, (1990-1991)
- Fellowship, Royal Netherlands Academy of Arts and Sciences (Ter Meulen Fonds), The Netherlands, (1989-1991)
- Fellowship, Netherlands Cancer Foundation (Koningin Wilhelmina Fonds), The Netherlands, (1987-1989)
June 28, 2013: PhD committee for Lauren Hanly, University of Western Ontario